Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 265Leukemia, Lymphocytic, Chronic, B-Cell 66Lymphoma, Large B-Cell, Diffuse 60Neoplasms, Plasma Cell 50Lymphoma, Follicular 45Lymphoma, Mantle-Cell 42Lymphoma 41Recurrence 38Lymphoma, B-Cell, Marginal Zone 31Leukemia 30Leukemia, Myeloid, Acute 27Lymphoma, B-Cell 19Lymphoma, Non-Hodgkin 17Myelodysplastic Syndromes 16Waldenstrom Macroglobulinemia 15Smoldering Multiple Myeloma 13Hodgkin Disease 13Lymphoma, T-Cell, Peripheral 12Neoplasms 11Lymphoma, T-Cell 9Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Immunoglobulin Light-chain Amyloidosis 8Burkitt Lymphoma 8Sezary Syndrome 7Neoplasm, Residual 7Mycosis Fungoides 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Plasma Cell 6

Interventions

trametinib 1ofatumumab 1liposomal amphotericin B 1dabrafenib 1Surveys and Questionnaires 1Ritonavir 1Quality of Life 1Povidone-Iodine 1Metformin 1Meropenem 1Lenalidomide 1Daptomycin 1Cloxacillin 1Ciprofloxacin 1Cilastatin, Imipenem Drug Combination 1Ceftazidime 1Cefepime 1Caspofungin 1Anti-Bacterial Agents 1Amoxicillin 1Amikacin 1Administration, Intravesical 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fever × Lenalidomide × Clear all
NCT01002755 2019-05-07

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled 7 charts
Classical hematologyLymphoidOther hematologic neoplasm

Lymphadenopathy, Agammaglobulinemia, Fatigue, Fever, Lymphocytosis, Paraproteinemias, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡